Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.

Gogola E, Duarte AA, de Ruiter JR, Wiegant WW, Schmid JA, de Bruijn R, James DI, Llobet SG, Vis DJ, Annunziato S, van den Broek B, Barazas M, Kersbergen A, van de Ven M, Tarsounas M, Ogilvie DJ, van Vugt M, Wessels LFA, Bartkova J, Gromova I, Andújar-Sánchez M, Bartek J, Lopes M, van Attikum H, Borst P, Jonkers J, Rottenberg S.

Cancer Cell. 2019 Jun 10;35(6):950-952. doi: 10.1016/j.ccell.2019.05.012. No abstract available.

2.

Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.

Barazas M, Gasparini A, Huang Y, Küçükosmanoğlu A, Annunziato S, Bouwman P, Sol W, Kersbergen A, Proost N, de Korte-Grimmerink R, van de Ven M, Jonkers J, Borst GR, Rottenberg S.

Cancer Res. 2019 Feb 1;79(3):452-460. doi: 10.1158/0008-5472.CAN-18-2077. Epub 2018 Dec 10.

PMID:
30530501
3.

Lung morphogenesis is orchestrated through Grainyhead-like 2 (Grhl2) transcriptional programs.

Kersbergen A, Best SA, Dworkin S, Ah-Cann C, de Vries ME, Asselin-Labat ML, Ritchie ME, Jane SM, Sutherland KD.

Dev Biol. 2018 Nov 1;443(1):1-9. doi: 10.1016/j.ydbio.2018.09.002. Epub 2018 Sep 5.

PMID:
30194919
4.

FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium.

Best SA, Harapas CR, Kersbergen A, Rathi V, Asselin-Labat ML, Sutherland KD.

Oncogene. 2018 Nov;37(46):6096-6104. doi: 10.1038/s41388-018-0399-5. Epub 2018 Jul 10.

5.

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.

Gogola E, Duarte AA, de Ruiter JR, Wiegant WW, Schmid JA, de Bruijn R, James DI, Guerrero Llobet S, Vis DJ, Annunziato S, van den Broek B, Barazas M, Kersbergen A, van de Ven M, Tarsounas M, Ogilvie DJ, van Vugt M, Wessels LFA, Bartkova J, Gromova I, Andújar-Sánchez M, Bartek J, Lopes M, van Attikum H, Borst P, Jonkers J, Rottenberg S.

Cancer Cell. 2018 Jun 11;33(6):1078-1093.e12. doi: 10.1016/j.ccell.2018.05.008. Erratum in: Cancer Cell. 2019 Jun 10;35(6):950-952.

6.

Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment.

Best SA, De Souza DP, Kersbergen A, Policheni AN, Dayalan S, Tull D, Rathi V, Gray DH, Ritchie ME, McConville MJ, Sutherland KD.

Cell Metab. 2018 Apr 3;27(4):935-943.e4. doi: 10.1016/j.cmet.2018.02.006. Epub 2018 Mar 8.

7.

Combining Cell Type-Restricted Adenoviral Targeting with Immunostaining and Flow Cytometry to Identify Cells-of-Origin of Lung Cancer.

Best SA, Kersbergen A, Asselin-Labat ML, Sutherland KD.

Methods Mol Biol. 2018;1725:15-29. doi: 10.1007/978-1-4939-7568-6_2.

PMID:
29322405
8.

Selected Alkylating Agents Can Overcome Drug Tolerance of G0-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice.

Pajic M, Blatter S, Guyader C, Gonggrijp M, Kersbergen A, Küçükosmanoğlu A, Sol W, Drost R, Jonkers J, Borst P, Rottenberg S.

Clin Cancer Res. 2017 Nov 15;23(22):7020-7033. doi: 10.1158/1078-0432.CCR-17-1279. Epub 2017 Aug 18.

9.

REV7 counteracts DNA double-strand break resection and affects PARP inhibition.

Xu G, Chapman JR, Brandsma I, Yuan J, Mistrik M, Bouwman P, Bartkova J, Gogola E, Warmerdam D, Barazas M, Jaspers JE, Watanabe K, Pieterse M, Kersbergen A, Sol W, Celie PHN, Schouten PC, van den Broek B, Salman A, Nieuwland M, de Rink I, de Ronde J, Jalink K, Boulton SJ, Chen J, van Gent DC, Bartek J, Jonkers J, Borst P, Rottenberg S.

Nature. 2015 May 28;521(7553):541-544. doi: 10.1038/nature14328. Epub 2015 Mar 23.

10.

BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance.

Jaspers JE, Sol W, Kersbergen A, Schlicker A, Guyader C, Xu G, Wessels L, Borst P, Jonkers J, Rottenberg S.

Cancer Res. 2015 Feb 15;75(4):732-41. doi: 10.1158/0008-5472.CAN-14-0839. Epub 2014 Dec 15.

11.

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R, Wientjens E, Ji J, Aly A, Doroshow JH, Cranston A, Martin NM, Lau A, O'Connor MJ, Ganesan S, Borst P, Jonkers J, Rottenberg S.

Cancer Discov. 2013 Jan;3(1):68-81. doi: 10.1158/2159-8290.CD-12-0049. Epub 2012 Oct 25.

12.

Lack of ABCG2 shortens latency of BRCA1-deficient mammary tumors and this is not affected by genistein or resveratrol.

Zander SA, Kersbergen A, Sol W, Gonggrijp M, van de Wetering K, Jonkers J, Borst P, Rottenberg S.

Cancer Prev Res (Phila). 2012 Aug;5(8):1053-60. doi: 10.1158/1940-6207.CAPR-12-0050. Epub 2012 Jul 5.

13.

Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.

Rottenberg S, Vollebergh MA, de Hoon B, de Ronde J, Schouten PC, Kersbergen A, Zander SA, Pajic M, Jaspers JE, Jonkers M, Lodén M, Sol W, van der Burg E, Wesseling J, Gillet JP, Gottesman MM, Gribnau J, Wessels L, Linn SC, Jonkers J, Borst P.

Cancer Res. 2012 May 1;72(9):2350-61. doi: 10.1158/0008-5472.CAN-11-4201. Epub 2012 Mar 6.

14.

Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo.

Pajic M, Kersbergen A, van Diepen F, Pfauth A, Jonkers J, Borst P, Rottenberg S.

Cell Cycle. 2010 Sep 15;9(18):3780-91. Epub 2010 Sep 13.

15.

6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance.

Issaeva N, Thomas HD, Djureinovic T, Jaspers JE, Stoimenov I, Kyle S, Pedley N, Gottipati P, Zur R, Sleeth K, Chatzakos V, Mulligan EA, Lundin C, Gubanova E, Kersbergen A, Harris AL, Sharma RA, Rottenberg S, Curtin NJ, Helleday T.

Cancer Res. 2010 Aug 1;70(15):6268-76. doi: 10.1158/0008-5472.CAN-09-3416. Epub 2010 Jul 14. Erratum in: Cancer Res. 2010 Oct 1;70(19):7734. Djurenovic, Tatjana [corrected to Djureinovic, Tatjana].

16.

Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.

Zander SA, Kersbergen A, van der Burg E, de Water N, van Tellingen O, Gunnarsdottir S, Jaspers JE, Pajic M, Nygren AO, Jonkers J, Borst P, Rottenberg S.

Cancer Res. 2010 Feb 15;70(4):1700-10. doi: 10.1158/0008-5472.CAN-09-3367. Epub 2010 Feb 9.

17.

Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer.

Pajic M, Iyer JK, Kersbergen A, van der Burg E, Nygren AO, Jonkers J, Borst P, Rottenberg S.

Cancer Res. 2009 Aug 15;69(16):6396-404. doi: 10.1158/0008-5472.CAN-09-0041. Epub 2009 Aug 4.

18.

MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.

Verreck FA, Vervenne RA, Kondova I, van Kralingen KW, Remarque EJ, Braskamp G, van der Werff NM, Kersbergen A, Ottenhoff TH, Heidt PJ, Gilbert SC, Gicquel B, Hill AV, Martin C, McShane H, Thomas AW.

PLoS One. 2009;4(4):e5264. doi: 10.1371/journal.pone.0005264. Epub 2009 Apr 15. Erratum in: PLoS One. 2011;6(2). doi:10.1371/annotation/e599dafd-8208-4655-a792-21cb125f7f66.

19.

Noninvasive functional imaging of P-glycoprotein-mediated doxorubicin resistance in a mouse model of hereditary breast cancer to predict response, and assign P-gp inhibitor sensitivity.

van Leeuwen FW, Buckle T, Kersbergen A, Rottenberg S, Gilhuijs KG.

Eur J Nucl Med Mol Imaging. 2009 Mar;36(3):406-12. doi: 10.1007/s00259-008-1010-z. Epub 2008 Dec 18.

PMID:
19093112
20.

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.

Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NM, Borst P, Jonkers J.

Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84. doi: 10.1073/pnas.0806092105. Epub 2008 Oct 29.

21.

Preceptors' perceptions of clinical performance failure.

Hrobsky PE, Kersbergen AL.

J Nurs Educ. 2002 Dec;41(12):550-3. Review. No abstract available.

PMID:
12530571
22.

Managed care. Shifts health care from an altruistic model to a business framework.

Kersbergen AL.

Nurs Health Care Perspect. 2000 Mar-Apr;21(2):81-3.

PMID:
11143613
23.

Case management: a rich history of coordinating care to control costs.

Kersbergen AL.

Nurs Outlook. 1996 Jul-Aug;44(4):169-72.

PMID:
8871998
24.

Reinstating nursing administration graduate study in federal nurse traineeships.

Kersbergen AL.

J Nurs Adm. 1994 Jul-Aug;24(7-8):12-4.

PMID:
8057165

Supplemental Content

Loading ...
Support Center